GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

Earlier diagnoses and advancements in treatment options are providing hope for patients with endometrial cancer like Yaca.